Considering that this amino acid is essential for central nervous system (CNS) function and development ( We found a significant decline in plasma sarcosine levels in LC patients, which is also reported in critically ill COVID-19 patients ( Despite previous reports on the role of tryptophan/serotonin in anxiety and depression ( The lower arginine in LC patients as reported in acute COVID-19 ( Other metabolites such as L/D-aspartate and serine amino acids are enriched in the brain and their reduction/dysfunction have been associated with neurological disorders ( Notably, a lower ATP plasma level may imply the impact of LC on the glycolytic and mitochondria pathway for cellular energy production
Epithalon inhibits tumor growth and expression of HER-2/neu oncogene in breast tumors in transgenic mice characterized by accelerated aging

LMICs Low- and middle-income countries HICs High-income countries NK cells Natural killer cells TNF- Tumor necrosis factor- IL-1 Interleukin-1 IL-6 Interleukin-6 TLR-4 Toll-like receptor-4 LPS Lipopolysaccharide NLRP3 NOD-like receptor protein 3 ROS Reactive Oxygen Species NO Nitric oxide SIM Sepsis-induced Myopathy GLP-1R Glucagon-like peptide-1 receptor GLP-1 Glucagon-like peptide-1 GLP-1RA Glucagon-like peptide-1 receptor agonist PKA Protein kinase A PLC Phospholipase C ERK1/2 Extracellular signal-regulated kinase 1 and 2 DPP-4 Dipeptidyl peptidase-4 IL-1 Interleukin-1 MCP-1 Monocyte Chemoattractant Protein-1 IL-10 Interleukin-10 iNOS Inducible nitric oxide synthase eNOS Endothelial nitric oxide synthase CRP C-reactive protein MDA Malondialdehyde 8-OHdG 8-hydroxy-2deoxyguanosine ICU Intensive Care Unit SOD Superoxide dismutase GPx Glutathione peroxidase Nrf2 Nuclear factor erythroid 1-related factor 2 SAE Sepsis-associated encephalopathy mTOR Mammalian target of rapamycin DPP-4is Dipeptidyl peptidase-4 inhibitors Glossary References 1

however, when compared with semaglutide 1.0 mg in type 2 diabetes, in doses of 5 mg, 10 mg and 15 mg, tirzepatide resulted in significantly greater body-weight reductions [5]
Yin, J., Xing, H., & Ye, J